Results of a questionnaire-based study show higher body mass index (BMI) is associated with worse migraine symptoms and comorbidities.
New research indicates a body mass index (BMI) equal to or greater than 30 is associated with increased migraine chronification, headache days per month, and headache severity, compared with migraineurs with normal BMI. The abstract will be presented at the American Academy of Neurology’s 73rd Annual Meeting, being held virtually April 17-22, 2021.
Previous studies have found individuals classified as obese tend to have an increased risk of migraine chronification, in addition to an increased risk of headache comorbidities. For example, one study conducted in 2020 found that in individuals under the age of 50, both total body obesity and abdominal obesity were associated with greater migraine prevalence and attack frequency.
The prevalence of obesity has substantially increased in recent years, with the latest CDC data classifying 9% of the US population as severely obese and 42% as obese. Weight gain and obesity are also some of the leading risk factors for disease and death worldwide, and significantly contribute to increased risks of COVID-19 complications. According to the CDC, an adult BMI of 30 or higher is considered “within the obesity range.”
In order to quantify BMI in migraineurs and better understand its impact on migraine characteristics and comorbidities, researchers recruited those referred to a large tertiary headache clinic at the University of Washington.
Prior to their first visit, all participants (N = 3611) completed a detailed intake questionnaire on topics, including headache characteristics, sleep, depression, anxiety, stress, and other information. Patients’ BMI and diagnosis of migraine based on International Classification of Headache Disorders, 3rd Edition, criteria were also recorded.
Analyses revealed:
“Our data support our expectation that BMI ≥ 30 compared to normal BMI correlates with increased migraine chronification, increased headache days per month, and increased headache severity,” the researchers concluded. “BMI ≥ 30 compared to normal BMI also significantly correlates with measures of migraine comorbidities, such as anxiety, depression, and difficulty with sleep.”
Findings suggest that normalizing BMI may be protective against migraine chronification and might help improve associated comorbidities.
Reference
O’Fallon G, Dyess M, Haley H, et al. Body mass index and the brain in pain: influence of BMI level on migraine patients seen at a large tertiary headache center. Presented at: American Academy of Neurology 73rd Annual Meeting; April 17-22, 2021; Virtual. Accessed April 13, 2021. https://index.mirasmart.com/AAN2021/PDFfiles/AAN2021-002621.html
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen